PartnershipUpdated on 30 April 2026
AT-31 BIO: Leading the immunology shift with next-gen immunosuppressive breakthroughs for complex disorders.
About
AT-31 BIO Lab has developed GJK-012, a novel immunomodulatory substance for use in innovative eye drops to treat dry eye syndrome in patients with Sjögren's syndrome. The global dry eye market exceeds $6 billion annually, with a significant unmet treatment need for Sjögren's patients.
We are seeking partners for collaborative new drug development using GJK-012. If your organization is interested in co-development, clinical research, or licensing opportunities with this water-soluble immunosuppressant, please contact us.
Investment partners
We are seeking a capital partnership to accelerate our pipeline. The intended use of funds includes advancing GJK-012 through clinical trials, expanding our R&D team, and supporting the regulatory submission process. This targeted investment will help us deliver innovative eye care solutions to a substantial, underserved patient population.
New drug co-developers
We are open to joint R&D collaboration to leverage complementary expertise
Big Pharma (M&A)
We wish to discuss out-licensing our lead compound. GJK-012 is protected by a recently filed international patent application (patent-pending), ensuring exclusive rights and commercial advantage for future partners.
Similar opportunities
Partnership
Areas of Interest for international collaboration
Young Ho Kim
Chief Executive Officer at AT-31 BIO Inc.
Daegu, South Korea
Partnership
Areas of Interest for international collaboration
Young Ho Kim
Chief Executive Officer at AT-31 BIO Inc.
Daegu, South Korea
Project cooperation
Portfolio Company Collaboration: 20/20 OptimEyes Technologies
- Research
- Execution
- Technical
- Biotech, Pharma and Cosmetics
Renaud Jacquemart
CEO at Omnium Global
Burlington, Canada